Controversies in Advanced Endoscopy: Update in ERCP from DDW 2016



Topics

MDRO – An epidemic or mass hysteria?

 ERCP Safety and Technique – Do it better, faster and safer

 Cholangiocarcinoma – Paradigm-shifting Studies

News Headlines Everywhere...




So How Common is this?

Culture Results	Total # Cx n(%) = 303	Clinically Indicated n(%) = 25	Surveillance Cx n(%) = 278
Gram Neg Organism	163 (53.8)	15 (60)	148 (53.2)
Gram Pos Organism	187 (61.7)	18 (72)	169 (60.8)
Fungal	34 (11.2)	3 (12)	31 (11.1)
Total MDRO	14 (4.6)	3 (12)	11 (4)
CRE	5 (1.6)	2 (8)	3 (1)
MRSA	2 (0.7)	0 (0)	2 (0.7)
VRE	7 (2.3)	1 (4)	6 (2.2)

Gaddam, et al DDW #208



Some sobering facts....



*Kim, S 2016; GIE 83(6):1121-1129.

- 500,000 ERCPs/year
- 1.9 % scopes remain contaminated despite HLD
- 14.4% transmission rate*
- 53.3% of those colonized will become infected*

Not an isolated event



How Can We Find It (Beforehand)?

- Rectal Swabs (2) in 76 patients
- Assay compared to PCR
- 100% concordance
- Only CRE + test in index patient with sx
- Implications:
 - Increased Safety
 - Decrease process time

Xpert Carba-R® (Cephid, Inc)




Pannala, et al DDW #276

How can we stop it?

N-acetylcysteine (NAC) - Biofilm Disruptor

- N-acetyl derivative of L-cysteine, naturally occurring amino acid
 - Generic available
 - Used regularly in clinical medicine / endoscopy
- Mucolytic
- Pregnancy class B
- Biofilm-disruption and antibacterial properties

Dinicola S 2014 El Feky et al 2009 Aslam et al 2011



KAISER PERMANENTE. thrive

Endoscopy

- Exam completed
- Scope removed

- •t=0: Elevator channel Cx w/ sterile swab
- •Elevator channel submerged in 20% NAC or sterile water
- •Channel Cx'ed q 5 minutes to 30 minutes

Reprocessing


•t=30, Scope reprocessed as usual

CFU

- Agar plates cultured for 48-72 hours
- •Most optically dense ½ inch counted by 5x microscope

Kwok, et al DDW #210

Results



Kwok, et al DDW #210

Rectal Indomethacin in ERCP


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

A Randomized Trial of Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

B. Joseph Elmunzer, M.D., James M. Scheiman, M.D., Glen A. Lehman, M.D., Amitabh Chak, M.D., Patrick Mosler, M.D., Ph.D., Peter D.R. Higgins, M.D., Ph.D., Rodney A. Hayward, M.D., Joseph Romagnuolo, M.D., Grace H. Elta, M.D., Stuart Sherman, M.D., Akbar K. Waljee, M.D., Aparna Repaka, M.D., Matthew R. Atkinson, M.D., Gregory A. Cote, M.D., Richard S. Kwon, M.D., Lee McHenry, M.D., Cyrus R. Piraka, M.D., Erik J. Wamsteker, M.D., James L. Watkins, M.D., Sheryl J. Korsnes, M.A., Suzette E. Schmidt, B.S.N., C.C.R.P., Sarah M. Turner, B.S., Sylvia Nicholson, C.C.R.C., and Evan L. Fogel, M.D., for the U.S. Cooperative for Outcomes Research in Endoscopy (USCORE)


Pre- versus Post -ERCP Indomethacin



Luo, et al DDW #342



Prevalence of Anesthesia Use in the United States from 2010-2011



Wernli KJ, Brenner AT, Rutter CM, Inadomi JM. Risks Associated With Anesthesia Services During Colonoscopy. Gastroenterology. 2016 Apr;150(4):888-94.



Risk of AE with Anesthesia versus Standard Sedation in Colonoscopy

Table 2.Risk of 30-Day Outcomes by ORs and 95% Cls of the Association Between Use of Anesthesia Services and Standard Sedation

	Overall		Polypectomy		No polypectomy	
Outcomes	ORª	95% CI	ORª	95% CI	OR ^a	95% CI
Any complication	1.13	1.12–1.14	1.16	1.15–1.17	1.10	1.10–1.12
Colonic					_	
Perforation	1.07	1 00_1 15	1.26	1.09_1.52	1.04	0.88_1.24
Homorrhago	1.28	1 27_1 30	1.36	1 33_1 30	1.23	1 22_1 26
Abdominal pain	1.07	1.05-1.08	1.10	1.08-1.11	1.04	1.02-1.05
Anesthesia-associated outcome						
Pneumonia	1.03	1.00-1.06	1.02	0.98-1.06	1.02	1.00-1.07
Infoction	1.00	0.07 1.10	1.00	0.00 1.10	1.00	0.00 1.15
Complications secondary to anesthesia	1.15	1.05–1.28	1.19	1.04–1.37	1.10	0.96-1.20
Cardiopuimonary						
Hypotension	0.97	0.93-1.02	1.00	0.94-1.07	0.94	0.00-1.00
Myocardial infarction	0.98	0.95-1.01	0.98	0.94-1.02	0.98	0.94-1.03
Stroke and other central nervous system events	1.04	1.00-1.08	1.05	1.00-1.11	1.04	0.99-1.10

^aAdjusted for age, sex, Charlson comorbidity status, polypectomy status, provider/practice type, region, and year (continuous).

Wernli, K et al; Gastroenterol 2016 Apr;150(4):888-94

Use of MAC and GA Anesthesia Increases Risk of AEs

ORIGINAL ARTICLE

Increased Risk in EGD

Douglas O. Faigel, MD

Cleveland, Cincinnati, Ohio; Portland, Oregon; Scottsdale, Arizona, USA

ORIGINAL ARTICLE: Clinical Endoscopy

A prospective asses patient and endosc administered sedati 21%

lverse events and ith anesthesiologist-

Tyler M. Berzin, MD, Sirish Sanaka, MD, Sheila R. Barnett, MD, Eswar Sundar, MD, Paul S. Sepe, MD, Moshe Jakubowski, PhD, Douglas K. Pleskow, MD, Ram Chuttani, MD, Mandeep S. Sawhney, MD

Boston, Massachusetts, USA

Optimal Sedation Type in ERCP

Adverse Event	Conscious Sedation (n=3615)	Monitored Anesthesia (n=1106)	Genera Anestho (n=1032	esia	
Hypoxia, n(%)	18 (22)	5 (25)	0 (0)	0.18	
Perforation, n(%) Bleeding General anesthesia but not MAC is Unable to associated with Risk Reduction procedure, n(%)					
OVERALL	83 (2.3)	15 (1.3)	8 (0.8)	<0.01	
Without "Fails"	1.8%	1.1%		0.0267	

Kesar, et al DDW #882



Cannulation Techniques: Does the Device make a difference?

	WIRE SYSTEM		'TOME TYP	Ξ
	Short (n=109)	Long (n=107)	Small (n=108)	Standard (n=108)
Safety Outcome				
Complication	3 (2.8%)	12 (11.2%)*	4 (3.7%)	11 (10.2%)
Post-ERCP Pancreatitis	3 (2.8%)	10 (9.3%)*	4 (3.7%)	9 (8.9%)
Efficacy Outcome				
Cannulation in < 8 attempts	81(74.3%)	80(74.8%)	80(74.1%)	81(75.0%)

Buxbaum et al DDW #275



^{*}p<0.05

Complete ES plus Large Balloon dilation (Balloon) versus ES+Mech lithotripsy (Standard) for CBD stones

Study Design

- Multicenter, 150 patients
- Randomized Balloon versus Standard
- Balloon 12-20 mm
 - Mean 16.79 ± 4.7 mm
- No difference in 2 groups:
 - # and size stones
 - CBD diameter
 - Periamp diverticula

Results

Outcome	Balloon	Standard	P-value
Clearance	96%	74%	<0.001
Cost (€)	477.4	623.5	0.029
Time (min)	39.11	49.63	0.015
AEs (%)	8.11	9.26	0.837

Karensti, et al DDW #264



Pre-surgical ERCP in Pancreatic AdenoCA


- Preop drainage: Assoc w/ severe morbidity¹
 - -73.5% versus 37.4% p<0.001
- PTC independent predictor for²:
 - Decreased survival
 - PTC 11.5 mos/ERCP 22.4 mos/ND 28.9 mos
 - Hepatic recurrence -HR 1.76, 95% CI(1.05-2.99)
- Very high (>15 mg/dl) preop bilirubin assoc.
 with severe postop morbidity³

¹Fang, Cochrane 2012;Strom, ²Surg Endosc 2015; ³Uemura, Ann Surg Oncol 2015



Preoperative ERCP for CholangioCA is Associated with Decreased Survival


Variable	HR	95% CI	P-value
ERCP	1.478	1.097-1.991	0.010
STAGE			
local	1 (Ref)		
regional	2.133	1.575-2.888	<0.001
distant	4.707	3.138-7.060	<0.001
CHARLSO	N INDEX	0 (ref)	
1	1.066	0.727-1.562	0.745
2	1.831	1.240-2.705	0.002
≥3	1.448	1.043-2.010	0.027



Median Survival (months – 95% CI): 11 (8-20) versus 31 (26-39)

Navaneethan, et al DDW #122

Preoperative ERCP for CholangioCA is Associated with Intrahepatic Recurrence



Multivariate analysis: age, gender, tumor differentiation, node status, lymphovascular invasion, preop bili level, preop drainage, CA 19-9 levels, post-op chemo and radiation therapy.

Factor	HR	95%CI	P-value
CA 19-9 > 200 IU	3.93	1.803- 8.569	0.001
Pre-op Drainage	3.203	1.098- 9.347	0.033

Jeong, et al DDW #123



Summary

- MDRO in ERCP scopes is rare; NAC may offer improved cleaning
- Pre- rather than Post- ERCP dosing of Indomethacin may be superior
- ERCP safer with Anesthesia-provided sedation
- Use of short-wires in ERCP decrease PEP
- Avoid pre-surgical ERCP in CholangioCA